Icatibant

Icatibant, the active ingredient in Icatibant, is a Bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It treats hereditary angioedema attacks in patients with a confirmed diagnosis.

GNH USA supplies Icatibant as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to treat conditions mediated by excessive bradykinin activity, particularly hereditary angioedema.

- Hereditary angioedema attacks: provides rapid relief of swelling and improves airway patency. - Hereditary angioedema type I: reduces edema during acute attacks. - Hereditary angioedema type II: reduces edema during acute attacks.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin redness. - Swelling at injection site: transient local edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate headache. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypersensitivity: rash, urticaria, or angioedema unrelated to HAE. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: low platelet count observed in rare cases. - Severe injection site necrosis: tissue damage at the site.

Before using Icatibant, consider the following safety measures.

- Assess airway: ensure the patient’s airway is stable before injection. - Monitor for hypersensitivity: observe for signs of allergic reaction after administration. - Use with caution in cardiovascular disease: patients with uncontrolled hypertension or heart failure should be closely monitored. - Avoid in known hypersensitivity: do not administer to individuals with documented allergy to icatibant or its excipients. - Report severe reactions: any anaphylaxis or serious skin reactions must be reported promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that influence bradykinin pathways or cause additive effects.

Major Interactions (Avoid): - ACE inhibitors: increase bradykinin levels and may reduce icatibant effectiveness. - Neprilysin inhibitors: elevate bradykinin concentrations, potentially diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate edema or hypersensitivity reactions. - Corticosteroids: concurrent use may mask early signs of allergic response. - Antihistamines: may require dose adjustment if combined with icatibant for severe reactions.